Meymandi Manzumeh-Shamsi, Keyhanfar Fariborz, Yazdanpanah Omid, Heravi Gioia
Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Pharmacology Department, Iran University of Medical Sciences, Tehran, Iran.
Anesth Pain Med. 2015 Oct 10;5(5):e28968. doi: 10.5812/aapm.28968. eCollection 2015 Oct.
Pregabalin as a new anticonvulsant has been used in different pain treatments.
The aim of this study was to investigate the role of N-methyl-D-aspartate (NMDA) ligands in antinociceptive effect of pregabalin in mice using tail flick.
NMDA (15 and 30 mg/kg) as an agonist or MK801 (0.02 and 0.05 mg/kg) as an antagonist were injected intraperitoneally either alone or 15 minutes before antinociceptive dose of pregabalin (100 mg/kg). Then the latency times and %MPE were measured in the tail flick assay during 75 minutes.
NMDA and MK801 had no effects alone. NMDA pretreatment significantly decreased the latency times of pregabalin till 75(th) minutes. In NMDA pretreated groups, %MPE30 unlike %MPE75 decreased significantly compared to those of pregabalin. MK801 delayed the latency times in pretreated groups, but %MPE30 and %MPE75 did not change significantly compared to pregabalin alone.
Our findings support the role of NMDARs in pregabalin antinociception, because the NMDAR agonist, unlike the antagonist, decreased the antinociceptive effect of pregabalin, even if tail flick is not an adequate pain assessment method in this regard.
普瑞巴林作为一种新型抗惊厥药物已被用于不同的疼痛治疗。
本研究旨在通过甩尾试验探究N-甲基-D-天冬氨酸（NMDA）配体在普瑞巴林对小鼠的抗伤害感受作用中的作用。
单独或在给予抗伤害感受剂量的普瑞巴林（100mg/kg）前15分钟腹腔注射NMDA（15mg/kg和30mg/kg）作为激动剂或MK801（0.02mg/kg和0.05mg/kg）作为拮抗剂。然后在75分钟内通过甩尾试验测量潜伏期和最大可能效应百分比（%MPE）。
NMDA和MK801单独使用时无效果。NMDA预处理显著缩短了普瑞巴林直至第75分钟的潜伏期。在NMDA预处理组中，与普瑞巴林组相比，%MPE30显著降低，而%MPE75无显著差异。MK801使预处理组的潜伏期延长，但与单独使用普瑞巴林相比，%MPE30和%MPE75无显著变化。
我们的研究结果支持N-甲基-D-天冬氨酸受体（NMDARs）在普瑞巴林抗伤害感受中的作用，因为与拮抗剂不同，NMDAR激动剂降低了普瑞巴林的抗伤害感受作用，尽管在这方面甩尾试验并非一种充分的疼痛评估方法。
